These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17340597)

  • 1. Current issues in non-inferiority trials.
    Fleming TR
    Stat Med; 2008 Feb; 27(3):317-32. PubMed ID: 17340597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855.
    Koch GG
    Stat Med; 2008 Feb; 27(3):333-42. PubMed ID: 17530625
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing non-inferiority: a combination approach.
    Gao P; Ware JH
    Stat Med; 2008 Feb; 27(3):392-406. PubMed ID: 17575568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferiority trials in surgical oncology.
    Fueglistaler P; Adamina M; Guller U
    Ann Surg Oncol; 2007 May; 14(5):1532-9. PubMed ID: 17294075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues on the selection of non-inferiority margin in clinical trials.
    Hou Y; Wu XY; Li K
    Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninferiority hypotheses and choice of noninferiority margin.
    Ng TH
    Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparisons in the comparative efficacy and non-inferiority settings.
    Snapinn S; Jiang Q
    Pharm Stat; 2011; 10(5):420-6. PubMed ID: 21956948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
    Wang YC; Chen G; Chi GY
    J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
    Durkalski VL; Berger VW
    Biom J; 2009 Feb; 51(1):185-92. PubMed ID: 19197960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
    Hung HM; Wang SJ; O'Neill R
    Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of clinical trials of gene therapy in Parkinson disease.
    Lewis TB; Standaert DG
    Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.